C4X Discovery
Alex has a proven track record in identifying, investing and growing businesses within the pharmaceutical sector. He is currently Chief Scientific Officer at 4D pharma plc.
From 2008, Alex was a director and shareholder of Aquarius Equity Partners Limited, and he joined the Board of C4XD as a Non-Executive Director following Aquarius’ investment in the Company. Prior to this, Alex worked for IP Group plc where he specialised in life science investments.
Alex has been involved in a number of private and public companies, including Nanoco Group plc, admitted to AIM in 2009; Retroscreen Virology Group plc, admitted to AIM in 2012; Tissue Regenix Group plc, admitted to AIM in 2010; and Auralis Limited, which, after investment through Aquarius Equity Partners Limited, delivered a seven-fold return through to its trade sale to ViroPharma Inc in 2010.
This person is not in the org chart
This person is not in any offices
C4X Discovery
C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies